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Mo lec u lar tar geted can cer ther apy is a prom is ing treat ment strat egy. Con sid er ing the cen tral
role of the epi der mal growth fac tor re cep tor in cell pro lif er a tion and sur vival, there are in di -
ca tions that tar geted agents like ty ro sine kinase in hib i tors, i. e., erlotinib, may en hance the
antitumor treat ment by ra di a tion. The aim of this study is to an a lyze the in ac ti va tion ef fects of 
g-rays and to test the radiosensitizing po ten tial of erlotinib on hu man lung adenocarcinoma
cells in vi tro. Ir ra di a tions were per formed with doses rang ing from 1 Gy to 8 Gy. In or der to
in crease the radiosensitivity of CRL-5876 lung adenocarcinoma cells, the cells were treated
with a clin i cally rel e vant con cen tra tion of 2 µM erlotinib. The ef fects of sin gle and com bined
treat ments were mon i tored us ing clonogenic sur vival, cell vi a bil ity and pro lif er a tion as says at
dif fer ent time points. For the de tec tion and vi su al iza tion of the phosphorylated histone
H2AX (g-H2AX), an im por tant bi o log i cal marker of DNA dou ble-strand break for ma tion,
flu o res cence immunocytochemistry, was per formed. The re sponse to the treat ment was mon -
i tored at four time points: 30 min, 2, 6, and 24 h. Ir ra di a tions with g-rays re sulted in sig nif i -
cant cell in ac ti va tion re gard ing all an a lyzed bi o log i cal end points. Com bined treat ments re -
vealed con sis tent cell in ac ti va tion. More over, com pared to g-rays alone, el e vated lev els of
g-H2AX foci were ob served af ter pre treat ment with erlotinib, in di cat ing radiosensitization
through im paired DNA re pair.
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IN TRO DUC TION
Lung can cer is the most fre quent cause of can cer
mor tal ity world wide [1]. This ag gres sive dis ease can be
sub di vided as small-cell lung car ci noma (SCLC) and
non-small-cell lung car ci noma (NSCLC) [2]. Within
NSCLC, rep re sent ing the ma jor ity of lung can cer cases,
adenocarcinoma is the most fre quently en coun tered his -
tol ogy [3]. The stag ing of lung can cer is es sen tial for de -
ter min ing the ap pro pri ate ther a peu tic ap proach. Sur gi cal
in ter ven tion is the most com mon treat ment for early
stage NSCLC. When di ag nosed close to 70% of pa tients
are al ready in the ad vanced stage of the dis ease [4]. Ra -
dio ther apy and che mo ther apy, alone or com bined, re -
main the most com mon op tion for these pa tients [5].
Can cer cells are less ef fec tive in re pair ing the ra di a -
tion-in duced dam age than nor mal cells, mak ing them
eas ier to be de stroyed if ra di a tion ther apy is ap plied [6].
In re cent years, new gen er a tions of drugs, i. e.,
tar geted ther a peu tics were de vel oped in or der to block
spe cific sig nal ing path ways in volved in can cer pro -
gres sion [7]. Cer tain mem bers of the fam ily of the epi -
der mal growth fac tor re cep tor (EGFR) genes have
been overexpressed or oth er wise de reg u lated in al -
most all ep i the lial tu mors, in clud ing NSCLC. This
alone, as well as the find ings on the im por tance of pro -
tein phosphorylation and the dis cov ery that the first
onco gene v-Src is a pro tein kinase, re sulted in se lect -
ing EGFR as the pri mary tar get of mo lec u lar tar geted
ther apy [8-10].
EGFR, a mem ber of the ErbB fam ily of re cep tor
ty ro sine kin ases, is a transmembrane glycoprotein con -
sist ing of a sin gle polypeptide chain and is found in ma -
jor ity of nor mal cells. The intracellular re gion of the
EGFR is in charge of pro tein ty ro sine kinase ac tiv ity
and plays an im por tant role in the reg u la tion of cell pro -
lif er a tion. EGFR fam ily mem bers are de reg u lated in
can cers by the fol low ing three mech a nisms: ac ti va tion
of gene mu ta tions, in creased num ber of gene cop ies (by
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am pli fi ca tion) and al tered ligand ex pres sion [11].
Overexpression of EGFR is found in 40% to 80% of pa -
tients with NSCLC. It is as so ci ated with poor prog no -
sis, since it also plays a spe cific role in the pro lif er a tion,
in va sion and me tas ta sis of ma lig nant cells [8, 12].
Most tar geted ther a pies in clude anti-EGFR
monoclonal an ti bod ies and small-mol e cule ty ro sine
kinase in hib i tors (TKI) [13]. Erlotinib hy dro chlo ride
(Tarceva®) is a quinazoline small-mol e cule in hib i tor
of the EGFR. It is an ac tive and well-tol er ated agent in
ad vanced NSCLC [14]. Erlotinib is ap proved for the
treat ment of pa tients with lo cally ad vanced or met a -
static NSCLC af ter fail ure of at least one prior che mo -
ther apy reg i men [15].
Ra di a tion in duces the ex pres sion of EGFR in
can cer cells, pos si bly con trib ut ing to the re sis tance of
those cells to ther apy [16, 17]. Overexpression of
EGFR by tu mors is also as so ci ated with re duced lo cal
con trol af ter ra di a tion [18]. Block ade of EGFR sig nal -
ling in vi tro has been proven to sen si tize cells to the ef -
fects of ra di a tion [16]. Con sid er ing the new in sights
into the role of EGFR in DNA re pair, there is sub stan -
tial in ter est in us ing EGFR in hib i tors for sen si tiz ing
tu mours to ra dio ther apy [17].
Sev eral stud ies have ana lysed the com bi na tion
of erlotinib with ra dio ther apy [16, 19, 20]. Clin i cal re -
ports of NSCLC pa tients with brain me tas ta sis ex -
posed to whole-brain ra di a tion ther apy with a par al lel
ad min is tra tion of erlotinib dem on strate lon ger over all
sur vival with par tic u lar ben e fits marked for pa tients
with EGFR mu ta tions. The rate of these mu ta tions in
the ana lysed group was much higher than ex pected
[20]. 
Un der stand ing cel lu lar events and path ways un -
der ly ing the en hance ment of the ra di a tion re sponse by
EGFR in hi bi tion is im por tant for fur ther im prove ment 
of can cer treat ment strat egy. There fore, in this in vi tro
study, g-rays and erlotinib were com bined in or der to
test the radiosensitising po ten tial of erlotinib and, at
the same time, im prove anticancer ef fects. Combined
ef fects of these agents were fol lowed on the
CRL-5876 hu man NSCLC lung adenocarcinoma
cells. The cho sen bi o log i cal end points were:
clonogenic sur vival, cell vi a bil ity and pro lif er a tion.
The level of ra di a tion sen si tiv ity is al most ex clu sively
as sessed using clonogenic as say (CA) con sid ered as
the gold stan dard. Colorimetric vi a bil ity as says, such
as sulforhodamine B (SRB) or 5-bromo-2'-
deoxyuridine (BrdU) test are ba si cally used for the  as -
sess ment of cel lu lar chemosensitivity. These tests are
re lated to the to tal cell num ber or the cor re spond ing
pro lif er a tion ca pac ity of the cells, while the
clonogenic as say mea sures the sur vival of col o nies
[21]. All of the men tioned as says were spe cif i cally se -
lected to sup port the com par i son of cell in ac ti va tion
ef fects pro duced by es sen tially dif fer ent agents: ra di a -
tion by g-rays and radiosensitization via erlotinib.
Phosphorylation of histone H2AX (g-H2AX) was
used for the de tec tion of DNA dou ble-strand breaks
in duced by ion iz ing ra di a tion and was eval u ated at dif -
fer ent time points. This ki netic study en abled the de -
tec tion of re sid ual DNA dam age at the level of in di vid -
ual cells. The re la tion ship be tween the loss of
clonogenic abil ity and the  re ten tion of g-H2AX foci
holds for drugs that dam age DNA by dif fer ent mech a -
nisms [22]. Com bin ing these ex per i men tal meth ods,
ad di tional data for the de sign of new ther a peu tic ap -
proaches will be ob tained.
MA TE RIAL AND METH ODS
Cell cul ture
Hu man NSCLC CRL-5876 cells were pur -
chased from the Amer i can Type Cul ture Col lec tion
(ATCC, Manassas, Va, USA) and were cul tured in the
RPMI 1640 me dium (Sigma-Aldrich Chemie GmbH,
Steinheim, Ger many) sup ple mented with 10% foe tal
calf se rum (FCS) (Sigma-Aldrich Chemie GmbH) and 
pen i cil lin/strep to my cin (Sigma-Aldrich Chemie
GmbH). Cells were main tained in a hu mid i fied at mo -
sphere of 5% CO2 at 37 °C (Heraeus, Hanau, Ger -
many).
Ir ra di a tion pro ce dure and
erlotinib prep a ra tion
CRL-5876 cells were ex posed to g-rays and/or
erlotinib in the ex po nen tial phase of growth. Ir ra di a -
tions with 60Co g-rays were per formed at the Vin~a In -
sti tute of Nu clear Sci ences, Bel grade, Ser bia. The de -
liv ered  sin gle  doses  were  in  the  range  from  1 Gy to
8 Gy at the dose rate of ~1 Gy/min. For the as sess ment
of g-H2AX foci, cells were ir ra di ated with a dose of
0.1 Gy at the same dose rate. All cell ir ra di a tions were
per formed at room tem per a ture, ex cept for the
immunocytochemistry pro ce dure in volv ing ir ra di a -
tions per formed at ~0 ºC. Erlotinib (Tarceva®) was
pur chased from Roche Di ag nos tics GmbH,
Mannheim, Ger many. The 10 mM stock so lu tion was
ob tained by dis so lu tion in dimethylsulphoside
(DMSO; SERVA Elec tro pho re sis GmbH, Hei del berg,
Ger many). That stock so lu tion was then se ri ally di -
luted in a cell cul ture me dium. Con sid er ing that 2 µM
of erlotinib cor re spond to clin i cally rel e vant doses,
this con cen tra tion was cho sen for the anal y sis of sin -
gle and com bined treat ments with g-rays. The fi nal
con cen tra tion of DMSO in cell sam ples did not ex ceed 
0.1%. In ac cor dance with data cited in lit er a ture, the
drug was ad min is tered 1 h prior to ra di a tion and main -
tained through out the ex per i ment [23].
O. D. Keta, et al.: Radiosensitization of Non-Small Cell Lung Car ci noma by ...
234 Nu clear Tech nol ogy & Ra di a tion Pro tec tion: Year 2014, Vol. 29, No. 3, pp. 233-241
Clonogenic as say
CA was per formed ac cord ing to the pre vi ously
de scribed pro to col [24, 25]. Cells were har vested im -
me di ately af ter ir ra di a tion and/or erlotinib pre treat -
ment and seeded at a suit able num ber in trip li cate, in
6-well plates. A 7 day time point was cho sen for the
eval u a tion of radiobiological ef fects, since it en ables
at least six dou bling times fol low ing ir ra di a tion [26].
Af ter the in cu ba tion pe riod of 7 days, cells were rinsed
care fully with phos phate- buf fered sa line (PBS), fixed
with meth a nol (Zorka Pharma, Šabac, Ser bia), stained
with 0.5% Crys tal Vi o let (Al lied Chem i cal, New York, 
USA) in 25% meth a nol for 10 min. Af ter that, the crys -
tal vi o let was re moved, dishes were rinsed with tap
wa ter and left to dry at room tem per a ture. Col o nies
con sist ing of 50 or more cells were counted un der the
in verted mi cro scope. The sur vival frac tion of treated
cells was de ter mined by com par ing the num ber of col -
o nies in treated sam ples with those in con trol. Dig i tal
im ages from 6-well plates were taken and col ony sizes
mea sured us ing ImageJ soft ware [27].
Cell vi a bil ity as say
The Sulforhodamine B (SRB) as say was used
for cell den sity de ter mi na tion [28]. In or der to check
the re sults ob tained by the clonogenic as say, these re -
sults were com pared with SRB data [21]. To de fine the
ex per i men tal con di tions in the SRB as say, ex po nen -
tially grow ing cells were treated with 2 µM erlotinib
for 24, 48, and 72 h. The most pro nounced sin gle ef -
fect of erlotinib was ob tained at the 72 h time point.
There fore, vi a bil ity tests were per formed 72 h and 7
days af ter the treat ment of CRL-5876 cells.  The SRB
as say is based on the mea sure ment of the cel lu lar pro -
tein con tent. The solubilized dye, SRB, binds to the
ba sic amino ac ids of cel lu lar pro teins. The colorime-
tric mea sure ment of the bound dye pro vides data on
the to tal pro tein con tent that is cor re lated with the cell
num ber. Cells were seeded in 96-well plates at a den -
sity of 1000 cells per well and treated in the ex po nen -
tial phase of growth. Af ter wards, cho sen in cu ba tion
pe riod cells were fixed with 10% trichloroacetic acid
and stained with 0.4% SRB (Sigma-Aldrich Chemie
GmbH) for 15 min. The ex cess dye was re moved by
wash ing with 1% ace tic acid. The pro tein-bound dye
was dis solved in a 10 mM Tris base so lu tion for
absorbance de ter mi na tion, at 550 nm, us ing a
microplate reader (Wallac, VICTOR2 1420 Multilabel 
coun ter, Turku, Fin land).
Cell pro lif er a tion as say
The 5-bromo-2'-deoxyuridine (BrdU) as say
(Roche Di ag nos tics GmbH) was used to mea sure cell
pro lif er a tion by quan ti fy ing BrdU that is in cor po rated
into the newly syn the sized DNA of rep li cat ing cells.
The as say was per formed ac cord ing to the man u fac -
turer's in struc tions and at the same time points as the
SRB as say (72 h and 7 days af ter treat ment). The cells
were in cu bated with the BrdU la bel ing so lu tion for 2
h, fixed and in cu bated with the anti-BrdU-POD an ti -
body. Af ter re mov ing the an ti body, the sub strate so lu -
tion was added and in cu bated un til the dye was de vel -
oped (from 5 to 30 min). The re ac tion was stopped by
add ing the 1M H2SO4 so lu tion. Absorbance was mea -
sured us ing a microplate reader (Wallac, VICTOR2
1420 Multilabel coun ter) at a test wave length of 450
nm.
Immunofluorescence stain ing
for de tec tion of g-H2AX foci
For the de tec tion of g-H2AX, the pri mary (di -
rect) immunofluorescence pro ce dure was used.
Briefly, cells were grown on glass cover slips in 6-well
dishes, over night, in or der to at tach to the sur face. At
0.5, 2, 6, and 24 h posttreatment, the me dium was as pi -
rated and cells washed with cold PBS.  The cells were
then  fixed  with ice-cold ac e tone-meth a nol (1:1) for
30 min at –20 ºC. Fol low ing fix a tion, the cells were
washed again with PBS and blocked with a 5% bo vine
se rum al bu min (BSA, Frac tion V; Sigma-Aldrich
Chemie GmbH) in PBS for 1 h at room tem per a ture.
They were then in cu bated over night at 4 ºC with pri -
mary Alexa Fluor® 488 anti-H2AX Phosphorilated
(Ser 139) an ti body (BioLegend, San Diego, Cal.,
USA) at 1:500 di lu tion. Af ter in cu ba tion, the cells 
were  washed  5  times,  each for 10 min, with PBS 
Tween  20  (PBST)  and  counter stained  with  DAPI
(4',   6-diamidino-2-phenylindole   dihydrochlo-  ride,
1 µg/ml; Sigma-Aldrich Chemie GmbH) in PBS. Fol -
low ing ex ten sive wash ing in PBST, cover slips were
mounted on glass slides with the Mowiol® 4-88
antifade mount ing me dium (Sigma-Aldrich Chemie
GmbH). Slides were then sealed and ex am ined us ing a
con fo cal la ser scan ning mi cro scope, Leica TCS SP5 II 
(Leica Mi cro sys tems CMS GmbH, Wetzlar, Ger -
many) and LAS AF Lite soft ware (Leica Mi cro sys -
tems CMS GmbH). The im ages were pro cessed and
the num ber of g-H2AX foci was de ter mined us ing
CellProfiler im age anal y sis soft ware. Cells with more
than 10 foci were con sid ered as foci-pos i tive. In each
ex per i ment, at least 50 foci-pos i tive cells were ex am -
ined.
Sta tis ti cal anal y sis
Dur ing each ex per i ment, mea sure ments were
made in trip li cate and each ex per i ment re peated three
times. The sta tis ti cal anal y sis was per formed us ing in -
de pend ent Stu dent's t-test and the value of p < 0.05
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con sid ered as sta tis ti cally sig nif i cant. The re sults were 
pre sented as the mean ± SEM (Stan dard Er ror of the
Mean).
RE SULTS
Sur vival of CRL-5876 cells
af ter erlotinib and g-rays
Clonogenic sur vival is the con ven tion ally used
cri te rion that il lus trates the level of cel lu lar
radiosensitivity. The sur vival of CRL-5876 cells was
an a lyzed af ter their ex po sure only to g-rays, as well as
af ter their com bined ex po sure to erlotinib and g-rays.
Ex per i men tal data were fit ted us ing the lin ear-qua -
dratic equa tion: S = exp(–aD – bD2), where S is the
sur viv ing frac tion for dose D, while a and b are the fit -
ting pa ram e ters.
The best fit curves of the data points for two ex -
per i men tal set ups ob tained by clonogenic as say 7 days 
af ter ir ra di a tion are pre sented in fig. 1(a), while the
cor re spond ing radiobiological data are given in tab. 1.
These re sults in di cate a rather high level of
radioresistance of the an a lyzed cells to lower doses of
g-rays (1 and 2 Gy). The es ti mated sur vival frac tion at
2 Gy (SF2) is 0.61. Start ing from 4 Gy, the re sponse of
CRL-5876 cells to g-rays is ma jor, show ing sig nif i cant 
cell in ac ti va tion, fig. 1(a). Pre treat ment of the ir ra di -
ated CRL-5876 cells with erlotinib causes higher in hi -
bi tion of cell sur vival with re spect to ir ra di a tion alone.
The   rel a tive  bi o log i cal  ef fec tive ness  at  2  Gy  (RBE
(2 Gy, g)) is 3.12. It is de fined as the ra tio of a 2 Gy
g-ray dose and a g-ray dose boosted by erlotinib that
pro duces the same in ac ti va tion level as that given by 2
Gy of the ref er ence g-rays. More over, the re duc tion in
col ony num ber is ac com pa nied by the re duc tion in col -
ony size, as il lus trated in fig. 1(b). An other com monly
used radiobiological pa ram e ter is the D10 value which
rep re sents the ra di a tion dose re quired to re duce sur -
vival to 10%. Pre treat ment with erlotinib leads to a
drop of D10 from 5.6 ± 0.6 to 2.9 ± 0.4. The
radiosensitization po ten tial of erlotinib is also il lus -
trated by the sen si ti za tion en hance ment ra tio (SER)
[29]. It is de fined as the ra tio of D10 with out the
sensitizer and D10 with the sensitizer, i. e., in this case,
erlotinib. The ob tained SER of 1.9 in di cates that the
in crease of sen si tiv ity to g-ir ra di a tion is in duced by
erlotinib (tab. 1). 
Vi a bil ity and pro lif er a tion of
CRL-5876 cells af ter erlotinib and g-rays
The SRB as say was per formed to as sess cell vi a -
bil ity af ter ir ra di a tion with out and with erlotinib pre -
treat ment. Ac cord ing to the data ob tained, 72 h af ter ir -
ra di a tion a ma jor dose-de pend ent re sponse to sin gle
g-rays with re spect to the con trol is ob served, fig. 2(a).
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Fig ure 1. (a) Dose-de pend ent sur vival curves of hu man
CRL-5876 cells af ter ir ra di a tion with g-rays and af ter
com bined treat ment with erlotinib and g-rays, ob tained
by clonogenic as say. The curves rep re sent the best fit of
the sur vival data to the lin ear-qua dratic equa tion.
Ir ra di a tion doses are 1, 2, 4, 6, and 8 Gy. Con cen tra tion
of erlotinib is 2 µM. Data ob tained from 3 ex per i ments
are pre sented as mean ± SEM; (b) Rel a tive re duc tion of
the CRL-5876 col ony size af ter sin gle and com bined
treat ment with 2 Gy g-rays and 2 µM erlotinib
Vi a bil ity is re duced for more than 50%. Both sin gle
and com bined treat ments show a sta tis ti cally sig nif i -
cant in hi bi tion of cell vi a bil ity com pared to the con trol 
cells (p < 0.001). CRL-5876 cells re veal a con sid er -
ably higher dose-de pend ent in ac ti va tion to com bined
treat ment, as com pared to sin gle treat ment with g-rays. 
At higher doses of ra di a tion, a slightly less pro -
nounced ef fect of erlotinib is no ticed (p < 0.001).
Erlotinib alone also de creases the vi a bil ity of the cells
72 h af ter ad min is tra tion (p < 0.01), fig. 2(a).
At 7 days of posttreatment with g-rays, higher ir -
ra di a tion doses of 6 Gy and 8 Gy pro voke a strong de -
cline in cell vi a bil ity. A better dose-de pend ent re -
sponse with com bined treat ment is ob served when
com pared to the 72 h time point. More over, at this time
point, vi a bil ity af ter com bined treat ments is sig nif i -
cantly dif fer ent with re spect to each sin gle treat ment
(p < 0.001 and p < 0.01 com pared to g-rays and
erlotinib, re spec tively), fig. 2(b).
Ac cord ing to the re sults ob tained by the BrdU
as say, 72 h af ter ex po sure to sin gle g-rays, cell pro lif -
er a tion de creases from 86% to 4% of the con trol value. 
Com bined treat ments pro voke an even stron ger and
sta tis ti cally sig nif i cant in hi bi tion of pro lif er a tion, not
ex ceed ing 10% of the con trol value, fig. 3(a). Nev er -
the less, at the 7 days' time point, cells in di cate pro lif er -
a tion  re cov ery for all treat ments, as com pared to the
72 h time point, fig. 3(b).
Ki net ics of g-H2AX foci for ma tion
In or der to eval u ate the ef fect of erlotinib pre -
treat ment on ir ra di a tion-in duced DNA dam age,
immunofluorescent stain ing of phosphorylated H2AX 
and con fo cal im age anal y ses were per formed 0.5, 2, 6,
and 24 h af ter ir ra di a tion. Rep re sen ta tive mi cro graphs
of the cells con tain ing g-H2AX foci are shown in fig.
4(a). Im me di ately af ter ex po sure to 0.1 Gy g-rays, the
num ber of g-H2AX foci in creases and af ter reach ing
the max i mum at 2 h, grad u ally de creases as the con se -
quence of DNA re pair. At 24 h postiradiation, the
num ber of foci de creases to the con trol level. Al -
though the in duc tion and ki net ics of the dis ap pear ance 
of g-H2AX foci is sim i lar in erlotinib pretreated cells,
sig nif i cant changes in the num ber of foci are ob served
only at 24 h posttreatment (p < 0.05), fig. 4(b).
DIS CUS SION
In con tem po rary med i cal prac tice, ra di a tion is
be ing used as an ef fec tive mo dal ity in can cer treat ment 
with the ul ti mate goal of pro vid ing the most op ti mal
ther a peu tic ef fect. Over the past years, the main chal -
lenges in can cer cure were fo cused on treat ment and
de liv ery plan ning, with the aim of im prov ing the ther -
a peu tic ef fects and min i miz ing cor re spond ing, un in -
tended, side ef fects. How ever, ra di a tion on col ogy is
faced with dose tol er ance lim i ta tions and, if it is to
prog ress fur ther and de liver better clin i cal out comes, it 
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Ta ble 1. Sur vival pa ram e ters, RBE and SER val ues for CRL-5876 cells
Treatment a [Gy–1] b [Gy–2] SF2 RBE [2 Gy, g] D10 [Gy] SER [D10]
g-rays 0.166 ± 0.059 0.042 ± 0.019 0.61 ± 0.01 1.00 5.6 ± 0.6 1
g-rays + erlotinib 0.789 ± 0.110 – 0.21 ± 0.01 3.12 ± 0.44 2.9 ± 0.4 1.9 ± 0.33
Data are pre sented as mean ± SEM
Fig ure 2. Vi a bil ity of CRL-5876 cells af ter sin gle and
com bined treat ments with g-rays and erlotinib
de ter mined by SRB 72 h (a) and 7 days (b) af ter
ir ra di a tion. Ir ra di a tion doses are 1, 2, 4, 6, and 8 Gy,
while the con cen tra tion of erlotinib (E) is 2 µM. Data
ob tained from 3 ex per i ments are pre sented as mean ±
SEM
(* – sin gle or com bined treat ment vs. con trol, † – com bined
treat ment vs. g-ir ra di a tion, # – com bined treat ment vs. sin gle 
drug treat ment; 0.01 < p < 0.05 (*, †, #), 0.001 < p < 0.01 (**, 
††, ##), p < 0.001 (***, †††, ###))
needs to in te grate bi o log i cal in no va tions into the ra di -
a tion ther apy [30]. Mo lec u lar tar geted drugs as mod -
ern radiosensitizing agents re ceive much at ten tion.
Pre clin i cal in vi tro and in vivo model sys tems may be
used to ex am ine mech a nisms un der ly ing tu mor
radiosensitization by these drugs [31]. The block ade
of the wild-type EGFR has also been dem on strated to
re duce ra di a tion re sis tance through three sep a rate
mech a nisms: by re duc ing DNA re pair, by in hib it ing
antiapoptotic path ways and by re duc ing pro lif er a tion
[16]. This study de scribes the abil ity of the EGFR ty -
ro sine kinase in hib i tor, erlotinib, to mod u late the ra di -
a tion re sponse in hu man CRL-5876 NSCLC
adenocarcinoma cells.
Sev eral pre clin i cal and clin i cal stud ies are un -
der way to eval u ate the com bi na tion of erlotinib with
ra dio ther apy [20, 32]. Since there is a lack of ba sic re -
search in this field, re cent in vi tro stud ies have been
de signed with erlotinib given be fore and/or af ter ra di -
a tion, but the op ti mal way of ad min is ter ing these
agents needs yet to be es tab lished [33]. In this ex per i -
men tal setup, erlotinib was added 1 h be fore ir ra di a -
tion, with pro longed in cu ba tion af ter ir ra di a tion when
the as says were per formed. A sim i lar ex per i men tal
setup was re ported by Wang and co work ers [23].
The bi o log i cal end points used in this work, i. e.,
clonogenic sur vival for the as sess ment of ra di a tion
dam age and colorimetric as says en abling the fol low
up of cel lu lar vi a bil ity af ter ad min is tra tion of dif fer ent
antitumour agents, were cho sen to al low for the com -
ple men tary anal y ses of the com bined treat ment that
was ap plied. All as says were per formed at ap pro pri ate
time points, thus en abling com par a tive in ves ti ga tion
of ob tained data. In ad di tion, the ki netic study of ap -
pear ance and dis ap pear ance of g-H2AX foci, par tic u -
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Fig ure 3. Pro lif er a tion of CRL-5876 cells af ter sin gle and 
com bined treat ments with g-rays and erlotinib re vealed
by BrdU 72 h (a) and 7 days (b) af ter ir ra di a tion.
Ir ra di a tion doses are 1, 2, 4, 6, and 8 Gy, while the
con cen tra tion of erlotinib (E) is 2 µM. Data ob tained
from 3 ex per i ments are pre sented as mean ± SEM
(* – sin gle or com bined treat ment vs. con trol, † – com bined
treat ment vs. g-ir ra di a tion, # – com bined treat ment vs. sin gle
drug treat ment; 0.01 < p < 0.05 (*, †, #), 0.001 < p < 0.01 (**,
††, ##), p < 0.001 (***, †††, ###)
Fig ure 4. (a) Dis tinc tive mi cro graphs of the cells con tain -
ing g-H2AX foci af ter sin gle and com bined treat ments
with g-rays and erlotinib, ob tained by con fo cal la ser
scan ning mi cro scope in or der to re veal ki net ics of
g-H2AX foci; (b) Ki net ics of ir ra di a tion-in duced
g-H2AX foci for ma tion af ter sin gle and com bined treat -
ments with g-rays and erlotinib. g-H2AX foci are de ter -
mined at the time points of 0.5, 2, 6, and 24 h. The
ir ra di a tion dose is 0.1 Gy while the con cen tra tion of
erlotinib is 2 µM. Con cen tra tion of DMSO cor re spond -
ing to that added with erlotinib so lu tion
larly ex tended to the time point of 24 h, was aimed to
cor re late the loss of clonogenic abil ity de tected by CA, 
with the re ten tion of DNA dam age-in duced foci,
there fore pro vid ing a com ple men tary ap proach [22].
As dem on strated by CA, with SF2 be ing 0.61,
the CRL-5876 cells can be con sid ered as
radioresistant, fig. 1(a). In com bined treat ment,
erlotinib in creased the radiosensitivity of CRL-5876
cells, reach ing 0.21 for SF2, whereas the D10 value
also changed from 5.6 to 2.9 Gy, thus giv ing a SER of
1.9 (tab. 1). The de crease in col ony num ber was ac -
com pa nied by a de crease in col ony size, fig. 1(b). A
sim i lar con duct of radiosensitivity as a func tion of
dose af ter treat ments with g-rays alone and in com bi -
na tion with erlotinib was ob served when cells were
an a lyzed by other vi a bil ity tests, such as SRB and
BrdU, figs. 2 and 3. Nev er the less, CA showed a stron -
ger in ac ti va tion of CRL-5876 cells than SRB and
BrdU as says. This can be ex plained by the fact that the
clonogenic as say mea sures only the ca pac ity of in di -
vid ual cells to form mac ro scopic col o nies, whilst vi a -
bil ity as says mea sure the to tal pro tein con tent (SRB
as say) or DNA rep li ca tion (BrdU as say). More over,
re cent data in di cate that ra di a tion and erlotinib can
cause growth ar rest by in duc ing ac cel er ated cell se -
nes cence [23]. Se nes cent cells re main met a bol i cally
ac tive for an ex tended time (up to 7 days af ter treat -
ment) and there fore would be scored as “sur vi vors” in
vi a bil ity as says [34].
Most of the can cer ther a peu tic agents, in clud ing
ra di a tion ther apy, di rectly or in di rectly in duce DNA
dou ble-strand breaks (DSB). If not prop erly re paired
by the cel lu lar re pair ma chin ery, these in ju ries are con -
sid ered le thal. One of the first cel lu lar re sponses to
these dam ages is phosphorylation of histone H2AX,
re sult ing in the for ma tion of dis tinct foci within min -
utes af ter the ini tial dam age [35]. Due to its ca pa bil ity
to dis tin guish mi cro scop i cally vis i ble foci in sin gle
cells, g-H2AX as say is widely ap plied in mon i tor ing
the ef fec tive ness of ra di a tion sensitizers [36]. Ex ploit -
ing the high sen si tiv ity of this as say, the im pact of
erlotinib on DSB re pair ki net ics af ter ra di a tion was
tested. To avoid foci over lap ping and, thus, the pos si -
ble un der es ti ma tion of their num ber at high doses, a
low ir ra di a tion dose, i. e., 0.1 Gy, was cho sen for the
in ves ti ga tion of the ex tent of the radiosensitizing ef -
fect of erlotinib. The re sults ob tained  show a sig nif i -
cantly higher num ber of foci in erlotinib-pretreated
cells 24 h af ter ra di a tion. It was pre vi ously re ported
that this re ten tion of g-H2AX foci is to be as so ci ated
with the loss of clonogenic po ten tial [37]. Sev eral
stud ies have shown that re pair-de fi cient cell lines pre -
serve more foci when an a lyzed 24 h af ter ir ra di a tion
[38, 39]. Cells that re tained unrepaired foci are prob a -
bly the cells that are in tended to die. The per cent age of
cells that pre served g-H2AX foci 24 h af ter ir ra di a tion
was cor re lated with the per cent age of cells that lost
clonogenicity, thus mak ing it pos si ble to use the frac -
tion of cells with re sid ual foci as a way to es ti mate sen -
si tiv ity to kill ing by ion iz ing ra di a tion [22, 40].
EGFR is in volved in sev eral crit i cal pro cesses in
DNA re pair that in clude im pact on translocation, tran -
scrip tion and phosphorylation of key pro teins and
genes re spon si ble for DNA re pair [41]. There fore, this
mul ti ple role of EGFR in the DNA re pair pro cess may
be the cause of the radiosensitization ef fects of
erlotinib on an a lyzed CRL-5876 cells. The mo lec u lar
mech a nisms by which erlotinib reg u lates DSB re pair
need fur ther in-depth in ves ti ga tion.
CON CLU SION
In sum mary, re sults re veal that g-rays in ac ti vate
CRL-5876 cells in a dose-de pend ent way. Pre treat -
ment with erlotinib sen si tizes the cells to g-rays, thus
mak ing this agent valu able in can cer treat ment when
used in syn ergy with ra di a tion. The in situ de tec tion of
g-H2AX foci was used in mon i tor ing the ef fec tive ness
of pre treat ment with the ra di a tion sensitizer. The es ti -
ma tion of an op ti mal ther a peu tic sched ule for the ad -
min is tra tion of erlotinib syn chro nized with ra di a tion
treat ment would be ben e fi cial for a com bined ther apy
ap proach.
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RADIOSENZIBILIZACIJA  NESITNO]ELIJSKOG
KARCINOMA  PLU]A  ^OVEKA  INHIBICIJOM  EGFR-a
Molekularno ciqana terapija kancera je va`an pristup za le~ewe ove bolesti. Imaju}i u 
vidu ulogu koju re cep tor za epidermalni faktor rasta ima na proliferaciju i pre`ivqavawe
}elija, postoje naznake da ciqani agensi, kao {to su inhibitori tirozin kinaza, npr. erlotinib,
mogu da pove}aju efikasnost zra~ewa u eliminaciji tumora. Ciq ove studije je analiza efekata
razli~itih doza gama zra~ewa kao i testirawe mogu}nosti erlotiniba da pove}a radioosetqivost
}elija humanog adenokarcinoma plu}a u in vi tro uslovima. Primewene su doze gama zra~ewa od 1 Gy do 
8 Gy. U nameri da se pove}a radioosetqivost CRL-5876 adenokarcinoma plu}a, }elije su tretirane
klini~ki relevantnom dozom erlotiniba od 2 mM. Efekti pojedina~nih i kombinovanih tretmana
su pra}eni pomo}u klonogenog pre`ivqavawa }elija, kao i wihove vijabilnosti i proliferacije u
razli~itim vremenskim ta~kama. Za detekciju i vizuelizaciju fosforilisanog histona H2AX
(g-H2AX), koji je va`an biomarker za pra}ewe stvarawa dvolan~anih prekida DNK, kori{}ena je
metoda fluorescentne imunocitohemije. Odgovor na tretmane je pra}en u ~etiri vremenske ta~ke:
30 minuta, 2, 6 i 24 ~asa. Ozra~ivawe gama zracima dovelo je do zna~ajne inaktivacije }elija na
nivou svih pra}enih biolo{kih parametara. Kombinovani tretmani su pokazali konzistentnu
}elijsku inaktivaciju. Tako|e, pove}an broj g-H2AX jedaraca je prime}en nakon pretretmana
erlotinibom u pore|ewu sa samim gama zra~ewem. Ovo ukazuje na pove}awe radioosetqivosti
}elija do koje je do{lo usled naru{ene DNK reparacije.
Kqu~ne re~i: }elija adenokarcinoma plu}a ~oveka, gama zra~ewe, DNK o{te}ewe, erlotinib,
.........................radiosenzibilizacija
